NEXUS™ Aortic Arch Stent Graft System First In Man Study

Inclusion Criteria: * Male and female age ≥ 18. * Any Thoracic Aorta pathology requiring landing in the Aortic Arch (zone 0, zone 1, zone2), e.g. aneurysm, dissection, false/Pseudo aneurysm. * In patient with a thoracic aneurysm: dilatation of the aortic arch larger than 5.5cm in diameter, or symptomatic aneurysm of the aortic arch, or aortic diameter growth rate \> 5mm per 6 months * Patient is considered an appropriate candidate for an elective surgery, as evaluated by Physical Status Classification System I, II or III (American Society of Anesthesiologists). * Femoral artery diameter as documented by CTA or MRA that allows endovascular access to the diseased site with a 20-22Fr delivery catheter. * Access vessels morphology suitable for endovascular repair in terms of tortuosity, calcification and angulation, documented by CTA, MRA. * Access vessel (femoral/iliac) diameter \> 7 mm * Ascending Aorta landing zone length \> 30 mm * Brachial/Axial Artery diameter \> 3 mm * Patient understands and is voluntarily willing to participate as evidenced by personally signing the Informed Consent document, and willingness to comply with follow-up schedule Exclusion Criteria: * Female is of childbearing potential * Life expectancy of less than 1 year * Any medical condition that, according to the investigator's decision, might expose the patient to increased risk by the investigational device or procedure. * Acutely ruptured or instable aneurysm or an acute vascular injury due to trauma or infected penetrating ulcers of the aorta. * Patient with an increased risk for aneurysm rupture during the procedure. * Patient whose arterial access site is not anticipated to accommodate the access of the Nexus™ Delivery System, due to size, tortuosity or hostile groins (scarring, obesity, or previous failed puncture) * Patients with severe atherosclerosis or intraluminal thrombus of the aorta or in the BCT * Patient is suffering from unstable angina or NYHA classification III and IV and/or ASA classification IV and above. * Patient has had a myocardial infarction (MI) or cerebral vascular accident (CVA) within 3 months prior to the planned implantation * Patient has a known hypersensitivity or contraindication to anticoagulants, antiplatelets, or contrast media, which is not amenable to pre-treatment. * Patient with a contraindication to undergo angiography * Patient with known sensitivities or allergies to the device materials- Nitinol and polyester * Clinical conditions that severely inhibit x-ray visualization of the Aorta. * Connective tissue disease (e.g., Marfan's or Ehler's-Danlos syndromes) * Patient has history of bleeding diathesis or coagulopathy that may limit the use of dual antiplatelet or anticoagulant therapy by the decision of the investigator * Patient has an active systemic infection at the time of the procedure documented by pain, fever, drainage, positive culture and/or leukocytosis (WBC \> 11,000 mm3). * Patients who have the condition that threatens to infect the stent graft. * Acute renal failure; chronic renal failure (excluding dialysis); Creatinine \> 2.00 mg/dl or \> 182 umol/L * Patient underwent major surgery or interventional procedure in the last three months. * Any other medical, social, or psychological issues that in the opinion of the investigator preclude them from receiving this treatment, or the procedures and evaluations pre- and post- treatment. * Active participation in another clinical trial that is reasonable to conflict with the NexusTM study.